tetano
Editor, Senior Moderator
ACS Appl Mater Interfaces
. 2021 May 9.
doi: 10.1021/acsami.1c05770. Online ahead of print.
Multichannel Immunosensor Platform for the Rapid Detection of SARS-CoV-2 and Influenza A(H1N1) Virus
Jianyong Li[SUP] 1 2 [/SUP], Rui Lin[SUP] 3 4 [/SUP], Yi Yang[SUP] 3 [/SUP], Rongtao Zhao[SUP] 3 [/SUP], Shiping Song[SUP] 5 [/SUP], Yi Zhou[SUP] 6 [/SUP], Jiye Shi[SUP] 1 2 [/SUP], Lihua Wang[SUP] 5 [/SUP], Hongbin Song[SUP] 3 [/SUP], Rongzhang Hao[SUP] 7 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) can present a similar syndrome to an influenza infection, which may complicate diagnosis and clinical management of these two important respiratory infectious diseases, especially during the peak season of influenza. A rapid and convenient point-of-care test (POCT) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus is of great importance for prompt and efficient control of these respiratory epidemics. Herein, a multichannel electrochemical immunoassay (MEIA) platform was developed based on a disposable screen-printed carbon electrode (SPCE) array for the on-site detection of SARS-CoV-2 and A(H1N1). The developed MEIA was constructed with eight channels and allowed rapid detection on a single array. On the SPCE surface, monoclonal antibodies against influenza A(H1N1) hemagglutinin (HA) protein or SARS-CoV-2 spike protein were coated to capture the target antigens, which then interacted with a horseradish peroxidase (HRP)-labeled detection antibody to form an immuno-sandwich complex. The results showed that the MEIA exhibited a broader linear range than ELISA and comparable sensitivity for A(H1N1) HA and SARS-CoV-2 spike protein. The detection results on 79 clinical samples for A(H1N1) suggested that the proposed MEIA platform showed comparable results with ELISA in sensitivity (with a positive rate of 100% for positive samples) but higher specificity, with a false-positive rate of 5.4% for negative samples versus that of 40.5% with ELISA. Thus, it offers great potential for the on-the-spot differential diagnosis of infected patients, which would significantly benefit the efficient control and prevent the spread of these infectious diseases in communities or resource-limited regions in the future.
Keywords: SARS-CoV-2; differential diagnosis; immunosensor; influenza A(H1N1) virus; multichannel.
. 2021 May 9.
doi: 10.1021/acsami.1c05770. Online ahead of print.
Multichannel Immunosensor Platform for the Rapid Detection of SARS-CoV-2 and Influenza A(H1N1) Virus
Jianyong Li[SUP] 1 2 [/SUP], Rui Lin[SUP] 3 4 [/SUP], Yi Yang[SUP] 3 [/SUP], Rongtao Zhao[SUP] 3 [/SUP], Shiping Song[SUP] 5 [/SUP], Yi Zhou[SUP] 6 [/SUP], Jiye Shi[SUP] 1 2 [/SUP], Lihua Wang[SUP] 5 [/SUP], Hongbin Song[SUP] 3 [/SUP], Rongzhang Hao[SUP] 7 [/SUP]
Affiliations
- PMID: 33966371
- DOI: 10.1021/acsami.1c05770
Abstract
The coronavirus disease 2019 (COVID-19) can present a similar syndrome to an influenza infection, which may complicate diagnosis and clinical management of these two important respiratory infectious diseases, especially during the peak season of influenza. A rapid and convenient point-of-care test (POCT) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus is of great importance for prompt and efficient control of these respiratory epidemics. Herein, a multichannel electrochemical immunoassay (MEIA) platform was developed based on a disposable screen-printed carbon electrode (SPCE) array for the on-site detection of SARS-CoV-2 and A(H1N1). The developed MEIA was constructed with eight channels and allowed rapid detection on a single array. On the SPCE surface, monoclonal antibodies against influenza A(H1N1) hemagglutinin (HA) protein or SARS-CoV-2 spike protein were coated to capture the target antigens, which then interacted with a horseradish peroxidase (HRP)-labeled detection antibody to form an immuno-sandwich complex. The results showed that the MEIA exhibited a broader linear range than ELISA and comparable sensitivity for A(H1N1) HA and SARS-CoV-2 spike protein. The detection results on 79 clinical samples for A(H1N1) suggested that the proposed MEIA platform showed comparable results with ELISA in sensitivity (with a positive rate of 100% for positive samples) but higher specificity, with a false-positive rate of 5.4% for negative samples versus that of 40.5% with ELISA. Thus, it offers great potential for the on-the-spot differential diagnosis of infected patients, which would significantly benefit the efficient control and prevent the spread of these infectious diseases in communities or resource-limited regions in the future.
Keywords: SARS-CoV-2; differential diagnosis; immunosensor; influenza A(H1N1) virus; multichannel.